Antengene Corporation Limited (HK:6996)
:6996
Want to see HK:6996 full AI Analyst Report?
Top Page
Antengene Corporation Limited
(6996)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$5.00
▼(-5.12% Downside)
Action:Reiterated
Date:05/08/26
The score is held back primarily by weak financial fundamentals (continued net losses and negative free cash flow despite improvement). Technical signals are also soft with the stock trading below key moving averages and weak momentum, while valuation offers limited support due to negative earnings and no dividend yield.
Positive Factors
Improving revenue growth
A materially stronger top-line in 2025 signals improving commercial traction in core Asian markets and better product adoption. Sustained revenue growth supports scale for R&D and commercialization, reducing per-unit costs and improving the odds of reaching self-funded operations over time.
Negative Factors
Persistent net losses
Sustained operating and net losses erode capital and limit internal reinvestment capacity. Until the company produces sustained positive operating income, it will remain dependent on external financing or partnerships, which can dilute shareholders and constrain strategic flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving revenue growth
A materially stronger top-line in 2025 signals improving commercial traction in core Asian markets and better product adoption. Sustained revenue growth supports scale for R&D and commercialization, reducing per-unit costs and improving the odds of reaching self-funded operations over time.
Read all positive factors
Antengene Corporation Limited (6996) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.89B
Dividend YieldN/A
Average Volume (3M)1.88M
Price to Earnings (P/E)―
Beta (1Y)2.25
Revenue Growth14.59%
EPS Growth22.41%
CountryHK
Employees169
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding679,446,660
10 Day Avg. Volume1,689,397
30 Day Avg. Volume1,876,149
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.32
Price to Sales (P/S)20.24
P/FCF Ratio-11.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.60Price Target Upside82.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.37
Revenue Forecast (FY)HK$703.70M
Antengene Corporation Limited Business Overview & Revenue Model
Company Description
Antengene Corporation Limited (6996) is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for cancer treatment. The company operates primarily in the biopharmaceutical sector, concentratin...
How the Company Makes Money
Antengene makes money primarily through (1) product sales from commercialized drugs where it holds commercialization rights in certain territories, (2) collaboration and licensing arrangements for its drug candidates and/or regional commercializat...
Antengene Corporation Limited Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
36
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 105.34M | 91.95M | 67.31M | 160.13M | 28.77M |
| Gross Profit | 86.83M | 74.17M | 55.01M | 132.00M | 24.19M |
| EBITDA | -221.25M | -348.82M | -550.31M | -866.06M | -614.32M |
| Net Income | -239.13M | -319.25M | -581.18M | -601.49M | -655.53M |
Balance Sheet | |||||
| Total Assets | 1.26B | 1.34B | 1.62B | 2.14B | 2.56B |
| Cash, Cash Equivalents and Short-Term Investments | 734.29M | 900.24M | 1.19B | 1.79B | 2.37B |
| Total Debt | 257.51M | 249.44M | 201.02M | 57.95M | 14.81M |
| Total Liabilities | 614.86M | 493.93M | 471.20M | 428.84M | 163.29M |
| Stockholders Equity | 642.70M | 850.80M | 1.15B | 1.71B | 2.39B |
Cash Flow | |||||
| Free Cash Flow | -178.86M | -382.57M | -778.87M | -665.56M | -581.04M |
| Operating Cash Flow | -127.51M | -321.96M | -665.77M | -572.18M | -557.65M |
| Investing Cash Flow | 116.16M | 345.24M | 587.07M | -208.16M | -103.88M |
| Financing Cash Flow | -3.19M | 45.17M | 131.84M | -20.73M | -81.29M |
Antengene Corporation Limited Technical Analysis
Negative
5.27
Price Trends
4.93
Negative
4.30
Positive
4.94
Negative
Market Momentum
-0.10
Positive
36.66
Neutral
13.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6996, the sentiment is Negative. The current price of 5.27 is above the 20-day moving average (MA) of 5.00, above the 50-day MA of 4.93, and above the 200-day MA of 4.94, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 36.66 is Neutral, neither overbought nor oversold. The STOCH value of 13.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6996.
Antengene Corporation Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$138.02B | 145.72 | 4.82% | ― | 38.55% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.33B | -15.87 | -6.26% | ― | -11.65% | -169.40% | |
50 Neutral | HK$39.90B | -256.36 | -10.78% | ― | 34.19% | 47.97% | |
50 Neutral | HK$12.15B | -15.04 | -64.19% | ― | -33.37% | -344.90% | |
46 Neutral | HK$2.89B | -8.92 | -26.73% | ― | 14.59% | 22.41% | |
44 Neutral | HK$14.37B | -6.78 | -123.74% | ― | -41.32% | -159.81% |
* Healthcare Sector Average
HK:6996
Antengene Corporation Limited
4.56
0.69
17.83%
HK:1801
Innovent Biologics
79.40
23.50
42.04%
HK:9966
Alphamab Oncology
8.55
-0.43
-4.79%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
23.16
6.22
36.72%
HK:2616
CStone Pharmaceuticals
7.70
4.04
110.38%
HK:6855
Ascentage Pharma Group International
38.80
-10.40
-21.14%
Antengene Corporation Limited Corporate Events
Antengene Moves to Modernize Governance as Global Oncology Portfolio Expands
Apr 29, 2026
Antengene Corporation Limited plans to amend its articles of association and adopt a ninth amended and restated memorandum and articles to enable hybrid or fully virtual shareholder meetings, align its governance with the Hong Kong treasury shares...
Antengene Sets 2026 AGM to Renew Governance Mandates and Share Issuance Authority
Apr 29, 2026
Antengene Corporation Limited has convened its annual general meeting for June 10, 2026, to be held both online and at its Shanghai premises, where shareholders will review and approve the audited financial statements for the year ended December 3...
Antengene Grants 1.9 Million Share Options and RSUs to Reward Key Talent
Apr 7, 2026
Antengene Corporation Limited has granted 1.9 million share options under its 2020 Equity Incentive Plan and 250,000 restricted share units under its 2022 RSU Scheme, with awards going to 52 grantees including one executive director and substantia...
Antengene Executives Boost Stakes in Vote of Confidence on Long-Term Growth
Mar 25, 2026
Antengene Corporation Limited reported that its founder, chairman and CEO, Dr. Jay Mei, increased his stake in the company by purchasing 200,000 shares on the open market, lifting his interest to about 27.16% of issued shares. Executive director a...
Antengene Narrows Losses on Cost Cuts as Revenue Climbs in 2025
Mar 20, 2026
Antengene Corporation Limited, a biopharmaceutical company specializing in oncology therapies, reported steady revenue growth driven primarily by accelerated contributions from Mainland China and strengthened commercialization partnerships. The co...
Antengene Schedules Board Meeting to Approve 2025 Annual Results
Mar 9, 2026
Antengene Corporation Limited has announced that its board of directors will convene on March 20, 2026, to review and approve the annual results of the company and its subsidiaries for the financial year ended December 31, 2025. The meeting will a...
Antengene Grants UCB Global Rights to ATG-201 in Autoimmune Disease Deal Worth Up to USD1.2 Billion
Mar 3, 2026
Antengene has signed a global license agreement granting UCB an exclusive worldwide license to develop, manufacture and commercialize ATG‑201, an investigational CD19/CD3 bispecific T‑cell engager for B cell‑related autoimmune di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.